ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought REGENXBIO securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 14, 2026, to serve as lead plaintiff [2]. - The lead plaintiff acts on behalf of other class members in directing the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Specifics - The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy for treating severe Mucopolysaccharidosis Type I, while concealing material adverse facts about its efficacy and safety [4]. - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data, which were later contradicted by the true details that emerged, leading to investor damages [4].